Key result
Glimepiride significantly decreased the cardio-ankle vascular index compared with glibenclamide (-0.50 vs -0.04; p=0.048) in patients with type 2 diabetes over 6 months.
Why the study?
Does glimepiride improve arterial stiffness assessed by CAVI in type 2 diabetic patients compared with glibenclamide?
RCT (n=40)
Does glimepiride improve arterial stiffness assessed by CAVI in type 2 diabetic patients compared with glibenclamide?
Absolute Event Rate: -0.5% vs -0.04%
p-value: p=0.048
Glimepiride significantly improves arterial stiffness (CAVI) compared to glibenclamide in patients with type 2 diabetes, potentially due to reduced oxidative stress.
No takes yet. Share an insight, caveat, or question.
Glimepiride's vascular effects on CAVI remain unproven in T2D; leaves open any advantage over other sulfonylureas.
Nagayama et al. (2010) conducted an RCT in Type 2 diabetes (n=40). Glimepiride vs. Glibenclamide 1.25 mg/day was evaluated on Change in cardio-ankle vascular index (CAVI) (p=0.048). Glimepiride significantly decreased the cardio-ankle vascular index compared with glibenclamide (-0.50 vs -0.04; p=0.048) in patients with type 2 diabetes over 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: